<DOC>
	<DOCNO>NCT00597493</DOCNO>
	<brief_summary>PURPOSE AND OBJECTIVES : Primary Objective To evaluate activity Sorafenib plus protract , daily temozolomide patient recurrent glioblastoma multiforme ( GBM ) measure 6-month PFS . Secondary Objectives To evaluate safety toxicity combination therapy use Sorafenib plus temozolomide ; To determine pharmacokinetics Sorafenib combine temozolomide patient concurrent EIAC medication .</brief_summary>
	<brief_title>Ph . 2 Sorafenib + Protracted Temozolomide Recurrent GBM</brief_title>
	<detailed_description>STUDY ACTIVITIES AND POPULATION GROUP : This open-label , non-randomized , single center phase 2 trial . A treatment cycle consist 4 week therapy . Sorafenib administer set dose 400 mg ( 2 x 200 mg tablet ) twice daily , without food ( least 1 hour 2 hour eat ) . Temozolomide administer set dose 50 mg/m2 daily without food ( least 1 hour 2 hour eat ) . Thirty-two ( 32 ) patient enrol single-stage study . DATA ANALYSIS AND RISK/SAFETY ISSUES : After 16 patient recurrent GBM treat , interim analysis conduct . If 6 patient experience unacceptable toxicity , accrual patient patient group terminate . Otherwise , patient accrual continue . If 9 total 32 patient experience unacceptable toxicity , treatment regimen consider unacceptable toxicity profile . The type I II error rate associate test 0.053 0.053 , respectively .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must histologically confirm diagnosis recurrent/progressive GBM . Recurrence distinguish `` pseudoprogression '' follow XRT/Temodar outline inclusion criterion 4.6 ( ) . Pts recurrent disease whose diagnostic pathology confirm glioblastoma multiforme need rebiopsy . Pts prior lowgrade glioma WHO grade III malignant glioma eligible histologic assessment demonstrate transformation GBM . Age &gt; 18 year . Pts must present 1st , 2nd 3rd relapse . Prior therapy must include external beam radiotherapy . Adequate bone marrow , liver renal function assess follow : Hemoglobin &gt; 9.0 g/dl Absolute neutrophil ct ( ANC ) &gt; 1,500/mm3 Platelet ct &gt; 100,000/mm3 Total bilirubin &lt; 1.5 x ULN ALT &amp; AST &lt; 2.5 x ULN ( &lt; 5 x ULN pts liver involvement ) INR &lt; 1.5 PT/PTT within normal limit ( unless therapeutic anticoagulation ) . Pts receive anticoagulation treatment agent warfarin heparin may allow participate . For pts warfarin , INR measure prior initiation sorafenib monitor least weekly , define local standard care , INR stable . Creatinine &lt; 1.5 x ULN An interval least 2 week prior surgical resection ( 1 week biopsy ) &amp; initiation study regimen ; An interval least 12 week completion standard , daily XRT , unless 1 follow occurs : 1 ) new area enhancement MRI image outside XRT field ; 2 ) biopsy proven recurrent tumor ; 3 ) radiographic evidence progressive tumor 2 consecutive scan least 4 week apart . An interval least 4 week prior chemotherapy ( except nitrosoureas require 6 week ) unless unequivocal evidence tumor progression pt recover anticipated toxicity prior therapy . Karnofsky performance score &gt; 60 % . Ability understand willingness sign write informed consent . A sign informed consent must obtain prior study specific procedure . If sexually active , patient take contraceptive measure ( barrier method birth control ) duration treatment 3 month follow discontinuation sorafenib &amp; temozolomide . Pts prior bevacizumab eligible however interval least 6 week must elapse since last dose . Prior treatment sorafenib . Significant cardiac disease include follow : ) congestive heart failure &gt; class II NYHA ; b ) unstable angina ( anginal symptom rest ) ; c ) new onset angina ( within last 3 month ) ; ) myocardial infarction within past 6 month ; e ) cardiac ventricular arrhythmia require antiarrhythmic therapy . Known severe hypersensitivity sorafenib excipients temozolomide . Excessive risk bleeding define stroke within prior 6 month , history CNS intraocular bleed , septic endocarditis . Female pt pregnant/breast feeding , adult reproductive potential employ effective method birth control . Concurrent severe and/or uncontrolled medical disease could compromise participation study uncontrolled diabetes , uncontrolled hypertension , active clinically serious infection &gt; CTCAE Grade 2 , history bleed diathesis coagulopathy , impairment GI function GI disease may significantly alter absorption study regimen ( i.e . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , bowel obstruction , inability swallow tablet ) . Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month Pulmonary hemorrhage/bleeding event &gt; CTCAE Grade 2 within 4 week 1st dose study drug . Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week 1st dose study drug . Serious nonhealing wound , ulcer , bone fracture . Major surgery , open biopsy significant traumatic injury within 4 week 1st study drug . Known human immunodeficiency virus ( HIV ) infection chronic Hepatitis B C. Pt &lt; 3 year free another primary malignancy except : primary malignancy currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow . Pts unwilling unable comply protocol include ability swallow whole pill presence malabsorption syndrome . Concurrent administration St. John 's Wort . Clinically serious infection require active intervention ( CTCAE grade 2 great ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Recurrent Glioblastoma Multiforme</keyword>
	<keyword>GBM</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Brain Tumor</keyword>
	<keyword>Recurrent GBM</keyword>
	<keyword>Temodar</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>Glioma</keyword>
	<keyword>Nexavar</keyword>
</DOC>